B+
Bull case
25%
Probability
Target price
$11.50
+49.4% vs current
KMDA
KamadaCNasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
At close
2026-06-02
AI scenario view
RankAlpha Sentiment CodexPost-earnings T+3Most likely
B
Base case
50%
Probability
Target price
$8.80
+14.3% vs current
B-
Bear case
25%
Probability
Target price
$6.40
-16.9% vs current
AI sentiment snapshot
Latest data as of 2026-05-16
Recent news sentiment (30D)
0.0
Mixed
Company
-
Unavailable
Macro
-
Unavailable
Pulse
-
Unavailable
Sentiment proxy
+67.3
Score
AI commentary
T+3 earnings follow-up leaves KMDA in a cautious monitoring bucket rather than a clean post-print upgrade. Primary company disclosures were constructive on guidance, demand and plasma expansion, but the quarter also showed gross-margin compression and shipment timing risk. Immediate analyst revision breadth and consensus surprise data are not available in the packet, so the post-earnings signal remains mixed; the May 15, 2026 anchor close of $7.71 suggests the market had not fully re-rated the story by the end of the week.
RankAlpha Sentiment Codex - 2026-05-16
Open post-earnings memoEvidence flagged
Coverage is limited for this name, so the memo relies on a thinner evidence base.; small-cap biotech memo lacks a distinct long-horizon program, partnership, or financing catalyst for a standard-conviction report
Impact
tentative
Confidence
-
AI events
2026-08-13catalystQ2 catch-up from delayed Q1 shipment plus reaffirmed FY26 outlook [#PR-2026-05-13]High impact
Kamada said Q1 2026 revenue was $45.2M, adjusted EBITDA was $11.6M and net income was $4.1M, while Q1 was affected by a temporary delay of a single order that was delivered in April. Management reaffirmed 2026 guidance of $200-$205M revenue and $50-$53M adjusted EBITDA, so the near-term test is whether the deferred shipment and stronger remainder-of-year framing show up cleanly in Q2 results.
2026-09-30catalystSan Antonio plasma center commercialization ramp [#PR-2026-05-13]High impact
Kamada said FDA approval of its San Antonio plasma collection center cleared the site to begin commercial sales of normal source plasma, and management described the three Texas plasma centers as a vertical-integration and capacity lever. Investor confidence still depends on evidence that the ramp contributes to revenue and margins over the next several quarters.
2026-12-31catalystBusiness-development or M&A execution using cash position [#PR-2026-05-13]High impact
Management said Kamada continues to evaluate near-term business development and M&A transactions intended to enrich the marketed-products portfolio and generate commercial synergies. The company reported $73.1M of cash, cash equivalents and short-term investments at March 31, 2026, but no specific transaction was announced, so this remains a low-visibility monitoring catalyst rather than a confirmed value driver.
Recommendation
N/A
No formal recommendation provided.
As of 2026-05-16 • Updated nightlySource: Internal modelMethodology